Thursday, 27 December 2018

EGFR-targeting trial or Tagrisso?

Looking at a possible clinical trial for my husband with an ADC (antibody-drug conjugate) called ABBV-321 that targets EGFR.  The trial has identified a maximum dose and is now in the expanded safety phase.  Any one know anything about this?  https://clinicaltrials.gov/ct2/show/NCT03234712

My husband's tumor is showing progression, so if he's deemed eligible for the trial then we'd be choosing between the trial or a combo of CCNU/Avastin/Tagrisso (the latter to target that EGFR amplification).  Choices, choices....


1 comment:

  1. To me, both of these sound like good options.

    Tagrisso has much better blood-brain barrier penetration compared to other EGFR inhibitors which have mixed success. Combinations also seem to be promising with a possible downside of side effects...

    On the other hand, ABBV-321 is comparable to ABT-414 (which has some interesting supportive data).

    I'd ask if the combination is possible in the event that ABBV-321 is not helpful.

    Dr. Kesari in Santa Monica seems to have an interest in this area, it would be good to get his weigh-in if that is possible.

    ReplyDelete